89bio Inc - Asset Resilience Ratio
89bio Inc (ETNB) has an Asset Resilience Ratio of 71.60% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 89bio Inc (ETNB) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2024)
This chart shows how 89bio Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 89bio Inc assets under control.
Liquid Assets Composition Over Time
This chart breaks down 89bio Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read 89bio Inc (ETNB) total liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $432.09 Million | 71.6% |
| Total Liquid Assets | $432.09 Million | 71.60% |
Asset Resilience Insights
- Very High Liquidity: 89bio Inc maintains exceptional liquid asset reserves at 71.60% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
89bio Inc Industry Peers by Asset Resilience Ratio
Compare 89bio Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for 89bio Inc (2020–2024)
The table below shows the annual Asset Resilience Ratio data for 89bio Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 65.57% | $313.89 Million | $478.69 Million | +21.52pp |
| 2023-12-31 | 44.06% | $262.71 Million | $596.27 Million | -23.47pp |
| 2022-12-31 | 67.52% | $132.91 Million | $196.82 Million | +7.01pp |
| 2021-12-31 | 60.51% | $98.29 Million | $162.42 Million | +10.08pp |
| 2020-12-31 | 50.43% | $106.45 Million | $211.07 Million | -- |
About 89bio Inc
89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of metabolic dysfunction-associated steatohepatitis and hypertriglyceridemia. 89bio, Inc. was formerly kn… Read more